Investigation of Zinc bis(1, 4-didecylbenzo)-bis(2, 3-pyrido) Porphyrazine for Application as Photosensitizer in Photodynamic Therapy of Cancer. (10th December 2007)

• Record Type: Journal Article
• Authors: Sakamoto, Keiichi; Ohno-Okumura, Eiko; Kato, Taku; Watanabe, Masaki; Cook, Michael J.
• Other Names: Swarts Jannie C. Academic Editor.
• Is Part Of: Metal-based drugs. Volume 2008(2008)
• Publication Date: 2007-12-10
• Subjects: Metals -- Therapeutic use -- Periodicals; Pharmaceutical chemistry -- Periodicals; Drugs -- Periodicals; Drugs; Metals -- Therapeutic use; Pharmaceutical chemistry; Chemistry, Pharmaceutical -- Periodicals; Metals -- therapeutic use -- Periodicals; Pharmaceutical Preparations -- Periodicals; Periodicals; Electronic journals; 615.23
• DOI: 10.1155/2008/392090
• Languages: English
• ISSNs: 0793-0291

Abstract

Abstract : The phthalocyanine analogue containing nonperipheral long alkyl-substituted benzenoid rings and pyridine rings, zinc bis(1, 4-didecylbenzo)-bis(2, 3-pyrido) porphyrazine, was synthesized. Zinc bis(1, 4-didecylbenzo)-bis(2, 3-pyrido) porphyrazine reacted with dimethyl sulfate and monochloroacetic acid to produce their quaternized products and diethyl sulfate to produce the sulfo-substituted products. All quaternized and sulfo-substituted showed amphiphilic character. Identical peaks in cyclic voltammograms appeared for these products before and after quaternization. During the evaluation of zinc bis(1, 4-didecylbenzo)-bis(2, 3-pyrido) porphyrazine for its photodynamic therapy of cancer (PDT) efficacy by cancer cell culture, the light exposed dimethyl sulfate quaternized zinc bis(1, 4-didecylbenzo)-bis(2, 3-pyrido) porphyrazines in IU-002 cells produce cell disruption that can be detected as a decrease in fluorescence.